Document Detail


Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
MedLine Citation:
PMID:  22692507     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Additional chromosomal abnormalities (ACAs) in Philadelphia-positive cells have been reported in ∼ 5% of patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP). Few studies addressing the prognostic significance of baseline ACAs in patients treated with imatinib have been published previously. The European LeukemiaNet recommendations suggest that the presence of ACAs at diagnosis is a "warning" for patients in early CP, but there is not much information about their outcome after therapy with tyrosine kinase inhibitors. To investigate the role of ACAs in early CP CML patients treated with imatinib mesylate, we performed an analysis in a large series of 559 patients enrolled in 3 prospective trials of the Gruppo Italiano Malattie Ematologiche dell'Adulto Working Party on CML: 378 patients were evaluable and ACAs occurred in 21 patients (5.6%). The overall cytogenetic and molecular response rates were significantly lower and the time to response was significantly longer in patients with ACAs. The long-term outcome of patients with ACAs was inferior, but the differences were not significant. The prognostic significance of each specific cytogenetic abnormality was not assessable. Therefore, we confirm that ACAs constitute an adverse prognostic factor in CML patients treated with imatinib as frontline therapy.
Authors:
Simona Luatti; Fausto Castagnetti; Giulia Marzocchi; Carmen Baldazzi; Gabriele Gugliotta; Ilaria Iacobucci; Giorgina Specchia; Lucia Zanatta; Giovanna Rege-Cambrin; Rege Cambrin; Marco Mancini; Elisabetta Abruzzese; Alfonso Zaccaria; Maria Grazia Grimoldi; Alessandro Gozzetti; Gaia Ameli; Maria Adele Capucci; Giandomenico Palka; Paolo Bernasconi; Francesca Palandri; Fabrizio Pane; Giuseppe Saglio; Giovanni Martinelli; Gianantonio Rosti; Michele Baccarani; Nicoletta Testoni;
Related Documents :
1708657 - Clinicopathologic study of changes in prolapsed intervertebral disks.
17264627 - Placental migration and mode of delivery in placenta previa: transvaginal sonographic a...
7839847 - Union after multiple anterior cervical fusion. 21 cases followed for 1-6 years.
6233717 - A comparative analysis of x-ray findings of the lumbar spine in patients with and witho...
18639777 - Endoscopic thoracic sympathectomy as a novel strategy for vasospastic angina refractory...
2993527 - Electrophysiological studies in the post-viral fatigue syndrome.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-06-12
Journal Detail:
Title:  Blood     Volume:  120     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-27     Completed Date:  2012-10-09     Revised Date:  2013-08-23    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  761-7     Citation Subset:  AIM; IM    
Affiliation:
Department of Hematology and Oncology L. e A. Seràgnoli, University of Bologna, Bologna, Italy.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00510926;  NCT00514488
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Chromosome Aberrations / chemically induced*
Cytogenetic Analysis
Female
Humans
In Situ Hybridization, Fluorescence
Leukemia, Myeloid, Chronic-Phase / drug therapy*,  genetics*,  mortality
Male
Middle Aged
Philadelphia Chromosome*
Piperazines / adverse effects*
Prognosis
Prospective Studies
Pyrimidines / adverse effects*
RNA, Messenger / genetics
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
Survival Rate
Young Adult
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 0/RNA, Messenger; BKJ8M8G5HI/imatinib
Comments/Corrections
Erratum In:
Blood. 2013 Jun 27;121(26):5259
Note: Cambrin, Rege [corrected to Rege-Cambrin, Giovanna]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignan...
Next Document:  Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leu...